Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1

Status

Active not recruiting 2Completed 1

Sponsor Class

NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 2Gynecologic 1

Conditions

Lung Neoplasms 29Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Carcinoma, Non-Small-Cell Lung 23Colorectal Neoplasms 16Melanoma 12Carcinoma, Renal Cell 12Carcinoma, Hepatocellular 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Glioblastoma 11Breast Neoplasms 11Triple Negative Breast Neoplasms 10Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 8Uterine Cervical Neoplasms 7Brenner Tumor 7Mycosis Fungoides 6Colonic Neoplasms 6Brain Neoplasms 6Rectal Neoplasms 5Multiple Myeloma 5Lymphoma, T-Cell, Cutaneous 5Endometrial Neoplasms 5Sezary Syndrome 4Sarcoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Lymphoma, Large B-Cell, Diffuse 4

Interventions

Cisplatin 55Carboplatin 50pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Docetaxel 17Cetuximab 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 12Radiation 11130-nm albumin-bound paclitaxel 11Sorafenib 10Platinum 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Sunitinib 8Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma × Immunoglobulin G × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡